IL6 and COVID-19: To sum up, our study is an open-label randomized trial that will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists as it aims to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia.